{‘She possesses little qualifications’: the US medical field prepares for Dr. Høeg's role at the Food and Drug Administration.

As the United States undertakes unprecedented revisions to its vaccination schedules, a particular individual has emerged somewhat surprisingly: Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines during the pandemic and has focused upon potential deaths following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Agency leaders were set to announce radical changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of alignment with many the world with no evidence for public health gain. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Høeg is listed to address the audience at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain pediatric shot schedules in the US to become more in line with Denmark, a nation with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no apparent track record in pharmaceutical research, approval processes or administrative roles, which has been typical for past directors of the CBER. She has worked at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a large organization. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that former directors who ran the center have had.”

This division has an vast portfolio at the FDA, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There’s a biosimilars division, over-the-counter program and other areas, and each of these need to be managed,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management component to the job, which oversees over 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

When asked about questions about Høeg’s credentials and whether this assignment indicates increased cooperation among agency officials on immunizations, a press secretary responded that the “concerns are based on inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her position,” the official explained, citing the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a controversial expedited therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being picked for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the FDA right now.”

Overall, he said, “the agency seems to be moving towards less stringent regulations of pharmaceuticals, aside from vaccines.”

Established History on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if concerning, past, Howard observe. She released a analysis using unconfirmed volunteer-provided data to estimate the incidence of heart inflammation following Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the current government included changing regulations for novel immunizations and halting “optional” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has according to sources floated the idea of barring teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough ideologue who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a very deceptive, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|